Abstract
Serum antimullerian hormone (AMH) is frequently used to predict a woman’s response to ovarian stimulation in assisted reproductive technology (ART). However, it has historically shown weak predictability for outcomes per embryo transfer (i.e. pregnancy and live birth rate) as traditionally reported by The Society for Assisted Reproductive Technology Clinic Outcome Reporting System (SARTCORS) prior to 2014. We hypothesized that the association of AMH with ART cumulative live birth rate (CLBR) per cycle start as reported from 2014 onward by SARTCORS may be more informative as CLBR accounts for the entire embryo cohort (fresh and frozen) that are created and linked to a single identified index retrieval.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
